Stroke is the fourth leading cause of death and the leading cause of long-term disability in the US (1 ) . Furthermore, the economic burden associated with stroke is estimated at 73.7 billion dollars (2 ), largely due to loss of earnings. The best known risk factors for stroke, such as hypertension, diabetes, smoking, and hypercholesterolemia, account for only Ͻ50% of stroke incidence (3 ) . Hence, there is great need to identify additional risk factors that might help identify people at risk for stroke.
Fetuin-A (␣2-Heremans-Schmid glycoprotein), a protein secreted primarily by the liver, has been associated with subclinical markers of cardiovascular disease (CVD) 6 (4, 5 ) , insulin resistance (6 ), type 2 diabetes (7 ), and incidence of total CVD (8 ) , particularly ischemic stroke (9 ) . However, the concentrations at which fetuin-A has a deleterious effect remain unclear. Low concentrations of fetuin-A have been associated with increased vascular calcification (5, 10 ) and CVD mortality (8, 11 ) . However, high concentrations have been associated with increased incidence of CVD (9 ) . Of note, several of the studies evaluating the association between fetuin-A and CVD incidence or mortality have been conducted among chronically ill populations (11, 12 ) . In a generally healthy middle-aged population, Weikert and colleagues (9 ) reported that indi-viduals in the highest quintile of fetuin-A had a 3-fold higher multivariable-adjusted risk of total CVD [relative risk (RR), 3.12; 95% CI, 2.15-4.52] and an even greater risk of ischemic stroke (RR, 3.66; 95% CI, 1.99 -6.71) compared to those in the lowest quintile. Further, Laughlin et al. (8 ) reported that the association between fetuin-A and CVD mortality varied by diabetes status, with a positive association among those without diabetes and an inverse association among those with diabetes. However, these associations have not been replicated by specific CVD endpoints, such as ischemic stroke.
We aimed to examine whether circulating fetuin-A was associated with risk of ischemic stroke among a cohort of women after adjustment for important cardiovascular risk factors. Furthermore, we sought to evaluate whether the association varied by key CVD risk factors, including age, body mass index (BMI), smoking, history of diabetes, hypertension, and postmenopausal hormone use.
Materials and Methods

NURSES' HEALTH STUDY COHORT
The Nurses' Health Study (NHS) enrolled 121 700 primarily white female registered nurses 30 -55 old years living in 11 US states who completed a mailed questionnaire in 1976. Follow-up questionnaires have been mailed biennially, with a semiquantitative food frequency questionnaire (FFQ) mailed approximately every 4 years since 1980. Detailed descriptions of the NHS have been published previously (13 ) . Over 90% of the baseline population has responded to follow-up questionnaires, and mortality follow-up is Ͼ98% complete (14 ) . Between 1989 and 1990, 32 826 participants, age 43-69 years, provided blood samples in collection tubes with sodium heparin. Additionally, approximately 10 years later (2000 -2001) 18 743 of these participants provided a second blood sample. Women had their blood drawn and shipped it to our laboratory via overnight courier for processing. Samples were processed and archived and have been continuously stored in monitored liquid nitrogen freezers (15 ) .
A nested case control study of ischemic stroke was conducted among those women with blood samples available. Among those, stroke cases were defined as women free of known prior stroke or cancer at the time of the blood collection, but with confirmed incident ischemic stroke during follow-up. For each stroke case, 1 control individual was selected from those women who were free of known prior stroke or cancer at the time of the blood collection and who did not have a stroke by the time of the index case. Controls were randomly selected eligible participants and matched to the index case by age (Ϯ2 years), race/ethnicity (white/ African-American/Asian/Hispanic/other/unknown), smoking (current/past/never at blood sample collection), menopausal status, postmenopausal hormone use at time of blood draw (yes/no), and date of sample collection. Approximately 75% of the women in this sample were fasting at the time of blood collection.
BLOOD SAMPLE ASSAY
Case-control pair samples were handled identically and shipped together to the laboratory in the same batch and assayed in the same run. Each batch included replicate, blinded plasma samples to assess laboratory precision, and "drift samples" standardized to a particular level for the biomarker to track and correct for laboratory assay drift. Total cholesterol, LDL cholesterol (LDL-C), HDL-C, high-sensitivity C-reactive protein (hs-CRP), and glycohemoglobin (Hb A 1C ) were measured in the Clinical and Epidemiological Research Laboratory at Children's Hospital (Boston, MA) for all cases and controls. Total cholesterol was measured enzymatically, with a mean intraassay CV of 4%. LDL-C was determined by a homogenous direct method from Roche Diagnostics with a mean intraassay CV of 3%. HDL-C concentration was determined using a direct enzymatic colorimetric assay, with a mean intraassay CV of 3%. CRP was assayed using a latex-enhanced immunonephelometric assay on a BN II analyzer (Dade-Behring) with a mean intraassay CV of 2%. HbA 1C levels were deter-mined by turbidimetric immunoinhibition using packed red blood cells with a Hitachi 911 analyzer (Roche Diagnostics) with an mean intraassay CV of 1.2%.
CEREBROVASCULAR DISEASE ASSESSMENT
We included confirmed ischemic strokes that occurred from the return of the blood sample (1989 -1990) through 2006, resulting in up to 17 years of follow-up. Nonfatal stroke was reported on biennial questionnaires and confirmed by medical records. Deaths were detected through information provided by the next of kin or postal authorities or determined by systematic searches of the National Death Index. In addition to death certificates, fatal stroke was also confirmed by review of hospital records or autopsy. Women (or next-of-kin for decedents) reporting stroke on follow-up questionnaires were asked for permission to review medical records, which were reviewed by a physician blinded to exposure status. Stroke was classified according to criteria established by the National Survey of Stroke (16 ) requiring evidence of a neurologic deficit with sudden or rapid onset that persisted for Ͼ24 h or until death. Strokes were classified as ischemic stroke due to thrombotic or embolic occlusion of a cerebral artery with imaging data from computed tomography or MRI or data on autopsy available for Ͼ92% of events. Reproducibility of our classification system is high (17 ) .
STATISTICAL ANALYSIS
Descriptive analyses for baseline characteristics were conducted comparing cases and controls and participants above and below the median concentration of fetuin-A. Fetuin-A, cholesterol/HDL-C, triglycerides, and CRP displayed skewed distributions; therefore, nonparametric statistical approaches were used in these analyses and covariates were log transformed. Fetuin-A was modeled as continuous (in spline models), in quartiles based on the control distribution, as ordinal quartiles to estimate linear trend, and dichotomized at the median value. In unadjusted analyses, median fetuin-A concentrations were compared across key characteristics. Spearman correlation coefficients adjusted for matching factors were calculated between fetuin-A concentrations, age, BMI, and CVD biomarkers. Conditional logistic regression models were used to evaluate the multivariable adjusted association of fetuin-A with ischemic stroke. Odds ratios (ORs) with 95% CIs were used to approximate the RR. Lifestyle and dietary covariates were used from the 1990 questionnaire or the closest year before 1990, with the exception of height (collected only in 1976).
We estimated 3 multivariable models. Model 1 was adjusted for matching factors (age, race/ethnicity, smoking, menopausal status, hormone therapy use, and date of sample collection). Model 2 was additionally adjusted for BMI (Ͻ18.5, 18.5-24.9, 25-29.9, Ն30 kg/m 2 ), aspirin use (Ͻ1 tablet/week, 1-5 tablets/week, Ͼ6 tablets/week), alcohol intake (0, Ͼ0 -4.9, 5-14.9, Ն15 g/day), physical activity (metabolic equivalents/ week-tertiles), alternate Healthy Eating Index 2010 (a score based on a diet low in trans-fat, red and processed meats, sodium, and sugar-sweetened beverages, while high in fruits and vegetables, nuts and legumes, polyunsaturated and -3 fats, and whole grains). Model 3 was further adjusted for history of diabetes (yes/no), hypertension (yes/no), coronary heart disease or revascularization (yes/no), Hb A 1c , and total/HDL-C and triglycerides (mg/dL). Physical activity, diet, hormonal status, and chronic disease outcomes (hypertension, diabetes, and heart disease) have been previously validated in this or similar populations (18 -21 ) . A missing indicator variable was used to model missing values for smoking and aspirin intake. Hb A 1c was missing in 16 case-control pairs, and the median value was imputed by case control status. We examined the possibly nonlinear relation between fetuin-A and ischemic stroke nonparametrically with restricted cubic and linear splines based on 4 knots located at 0.30, 0.40, 0.49, and 0.66 g/L (22) (23) (24) . Tests for nonlinearity used the likelihood ratio test, comparing a model with a linear term to a model with a linear and cubic spline terms.
Several sensitivity analyses were conducted. A priori we proposed to evaluate effect modification by selected risk factors: age (Ͻ65/Ն 65 years), BMI (Ͻ25/Ն25 kg/ m 2 ), smoking (nonsmoker/current), hypertension (yes/ no), diabetes status (yes/no), postmenopausal hormone use (yes/no), and time period of event occurrence (Ͻ8 years from baseline blood collection vs Ն8 years). A likelihood ratio test was used to assess the significance of interactions, comparing an unconditional main effects model adjusted for matching factors and covariates to one with interaction terms included. We conducted sensitivity analyses to calculate adjusted RRs and 95% CIs for measurement error correction in the fetuin-A measurements, by using the fetuin-A samples collected approximately 10 years apart. Additionally, we estimated the association between fetuin-A and ischemic stroke subtypes (thrombotic and embolic strokes). All P-values were 2-sided. Analyses were conducted with SAS for UNIX statistical software (version 9.1.3; SAS Institute).
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Results
The baseline descriptive characteristics of the 457 complete case-control pairs are presented in Table 1 . The mean age was 61 years. As expected, women who later developed ischemic stroke were more likely to be hypertensive, diabetic, and report a family history of heart disease and had borderline significantly higher CRP concentrations compared to controls. Median fetuin-A (g/L) concentrations were not significantly different between cases and controls.
In univariate analyses, median fetuin-A was significantly higher among participants with BMI Ն30 kg/ m 2 , total cholesterol Ն200 mg/dL, and CRP Ն3 mg/L and women with postmenopausal hormone use ( Table  2 ). In partial Spearman correlations, adjusted for matching factors, fetuin-A was significantly and positively correlated with total cholesterol, total cholesterol/HDL ratio, triglycerides, hs-CRP, and BMI (Table  3) ; with the strongest correlations observed for triglycerides followed by hs-CRP.
In multivariable analyses, quartiles of fetuin-A did not exhibit a significant association with risk of ischemic stroke (Table 4) . When adjusted for matching factors, the association between extreme quartiles was null (RR, 1.03; 95% CI, 0.69 -1.54). Results were virtually unchanged upon further adjustment for lifestyle factors (RR, 0.98; 95% CI, 0.65-1.49, extreme quartiles) or additional adjustment for chronic disease and biomarkers associated with stroke risk (RR, 1.03; 95% CI, 0.66 -1.60, extreme quartiles). We additionally modeled continuous fetuin-A concentrations and risk of ischemic stroke to examine any potential nonlinear association using restricted cubic splines; however, deviation from linearity was nonsignificant (Fig. 1) .
There was no evidence of effect modification with the relationship between fetuin-A and stroke by age, BMI, hypertension, diabetes, postmenopausal hormone use, and time period of event occurrence (all P interaction Ͼ 0.05) (See Table 1 in the Data Supplement that accompanies the online version of this report at http://www.clinchem.org/content/vol60/issue1). Additional analyses were conducted to correct for measurement error. These suggested that a larger sample size might be needed to determine the underlying association, as indicated by a wider CI in the corrected estimate (1 SD increase in fetuin-A: uncorrected RR, 1.00; 95% CI, 0.86 -1.16; corrected RR, 1.01; 95% CI, 0.64 -1.59). Estimates by ischemic stroke subtype were not materially different from the aggregate estimates Table 5 .
Discussion
In this sample of women, who were free of stroke at the time of blood collection and followed for up to 17 years, we observed that fetuin-A was positively associated with biomarkers of cardiovascular risk (i.e., blood lipids, triglycerides, and hs-CRP). In contrast to previous studies, we did not observe a significant association between fetuin-A concentrations and risk of ischemic stroke.
Fetuin-A has shown complex and divergent associations with cardiovascular outcomes, with reports of increased risk of subclinical cardiovascular outcomes and CVD events for both high and low fetuin-A concentrations (4, 5, 8, 10, 25, 26 ) . Only 2 previous studies have examined the association between fetuin-A and incident CVD in healthy populations, with inconsistent results (8, 9 ) . Higher fetuin-A was associated with a significantly greater risk of ischemic stroke among participants of the EPIC (European Prospective Investigation into Cancer and Nutrition)-Potsdam study, a European prospective cohort (highest vs lowest quintile: RR, 3.66; 95% CI, 1.99 -6.71), which was a stronger association than that observed for total CVD (highest quintile vs lowest: RR, 3.12; 95% CI, 2.15-4.52). Laughlin et al. (8 ) reported a significantly increased risk of CVD mortality with low fetuin-A and observed significant variation by diabetes status among participants of the Rancho Bernardo study, a community-based cohort of older adults. CVD mortality was significantly increased among nondiabetics in the lowest quartile of fetuin-A compared to quartiles Table 3 ).
Dashed lines represent 95% confidence bands, dotted line represents null value. We did not observe significant effect modification by diabetes status; however, our sample population was younger (mean age, 61 years) than that of the Rancho Bernardo Study (mean age, 72 years) and exhibited a lower prevalence of diabetes (6% controls, 12% cases), which was assessed by validated self-report rather than clinical measures, compared to the prevalence (14% overall) seen in the Rancho Bernardo study. Inconsistencies between study findings may be a result of variations in endpoints (CVD composite vs endpointspecific outcomes), evaluation of fatal vs nonfatal events, and differences in population characteristics (i.e., age, underlying chronic disease).
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Lower circulating fetuin-A concentrations have been associated with vascular calcification and cardiovascular mortality (4, 5, 10, 27 ) in both animal and human models. In contrast, high concentrations have been associated with carotid intima medial thickness (28 ) , an adverse atherogenic lipid profile (6, 29 ) , and an increased risk of insulin resistance (6 ), diabetes (7, 30 ) , and metabolic syndrome (29 ) . Although our results did not support a direct association between fetuin-A and ischemic stroke, we found evidence of an association with CVD risk factors, consistent with previous studies (9, 29 -31 ) . These associations may suggest an indirect role of fetuin-A in the pathogenesis of ischemic stroke through an influence on stroke risk factors, although not supported in these analyses. There may be a complex balance in the influence of fetuin-A concentrations on cardiometabolic outcomes owing to either insufficiency or excess; with the effects potentially dependent on underlying subclinical disease (e.g., atherosclerosis or insulin resistance) (32 ) . Our results, however, cannot confirm these hypotheses. Furthermore, we are unable to rule out the role of overall liver function because biomarkers of standard liver enzymes were not available for analysis.
Notable strengths of this work include the nested case control design, with 17 years of follow-up and fetuin-A samples collected before stroke events. Furthermore, we observed a moderate number of events, allowing for sensitivity analyses by key cardiovascular risk factors. However, we had limited power to evaluate ischemic stroke subtypes, particularly embolic strokes. Fetuin-A concentrations have been shown to be higher among women; therefore generalizability to men or ethnically diverse populations may be limited. While main analyses used a single measure of fetuin-A, we observed a moderate correlation between measures of fetuin-A over 10 years (ICC, 0.52; 95% CI, 0.42-0.62) and from our pilot study observed a high correlation between measures collected on average 1 year apart (ICC, 0.88; 95% CI, 0.76 -0.94). Furthermore, there was no significant evidence that the association between fetuin-A and ischemic stroke varied by time. We did not find evidence of an association between fetuin-A and risk of ischemic stroke in this sample of older women, in contrast to previously reported studies. Furthermore, we did not find evidence of significant variation of the association between fetuin-A and ischemic stroke by key CVD risk factors. Further research is needed to explore these associations in other populations.
